График акции GRAIL, LLC
Расширенный график
Простой график
О компании
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Выручка |
0.0556 |
Число акций ао |
0.0311 млрд |
Цена ао |
13.34 |
Валюта |
usd |
Сайт |
https://grail.com
|
IPO date |
2024-06-25 |
Sector |
Health Care |
Industry |
Biotechnology |
Валюта отчета |
usd |
Изменение цены за день: |
0% (14.09) |
Изменение цены за неделю: |
+4.53% (13.48) |
Изменение цены за месяц: |
-8.45% (15.39) |
|
Недооценка
Название |
Значение |
Оценка |
P/S |
0 |
0 |
P/BV |
0 |
0 |
P/E |
0 |
0 |
EV/EBITDA |
0 |
0 |
Итого: |
|
2.5 |
|
Эффективность
Название |
Значение |
Оценка |
ROA, % |
-29 |
0 |
ROE, % |
0 |
0 |
Итого: |
|
0 |
|
|
Дивиденды
Название |
Значение |
Оценка |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
Итого: |
|
0 |
|
Долг
Название |
Значение |
Оценка |
Debt/EBITDA |
0 |
10 |
Итого: |
|
10 |
|
Импульс роста
Название |
Значение |
Оценка |
Доходность Revenue, % |
537.15 |
10 |
Доходность Ebitda, % |
106.72 |
10 |
Доходность EPS, % |
424.4 |
10 |
Итого: |
|
10 |
|
Руководитель |
Должность |
Оплата |
Год рождения |
Mr. Robert P. Ragusa |
CEO & Director |
|
1960 (64 года) |
Dr. Joshua J. Ofman M.D., M.S.H.S |
President |
|
1965 (59 лет) |
Mr. Aaron Freidin |
Chief Financial Officer |
|
|
Mr. Paul Ciccolella |
Senior VP of Global Development & Operations |
|
|
Ms. Amoolya Singh Ph.D. |
Senior VP of Research & Chief Scientific Officer |
|
|
Mr. Abram Barth J.D., M.P.H. |
General Counsel |
|
|
Ms. Julie Currie |
Chief People Officer |
|
|
Mr. Rodger Currie |
VP and Head of Government Affairs & Alliance Development |
|
|
Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng |
President Biopharma Business & Europe |
|
|
Dr. Satnam Alag Ph.D. |
Senior VP of Software Engineering & Chief Security Officer |
|
|